Viridian reports phase 1 results for VRDN-008 autoimmune drug

🌐 Investing.com (Cyprus) —
Viridian reports phase 1 results for VRDN-008 autoimmune drug

AI Summary

Viridian reported Phase 1 results for VRDN-008, an investigational autoimmune drug. The provided article text contains no further information about the results, safety, or efficacy.

Markets Health Viridian VRDN-008 autoimmune disease clinical trial Phase 1

Read original source →